ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2071 entries already.
On the second day of SLAS 2025, the world’s largest laboratory automation conference in San Diego, the last two finalists of the Ignite Award pitched their business models. Meanwhile, the 10 finalists of the SLAS New Product Award showcased their systems in the Innovation AveNEW area of the exhibition.
Denmark’s complement system activator specialist Commit Biologics A/S has added a €5.5m extension to its €16.5 seed financing. New investor Korys joined Novo Holdings and Bioqube Ventures.
The world’s most important conference for laboratory automation and drug screening tools, SLAS 2025 International, opens today in San Diego. One of the highlights will be the pitches for the best start-up, the SLAS Ignite Award. European Biotechnology has taken a look at the technologies for you in advance.
Nippon Shinyaku has secured an option to acquire exclusive US rights to commercialize AB2 Bio’s tadekinig alfa to treat primary monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 mutation and XIAP deficiency.
Berlin-based food tech start-up Project Eaden is prepared to launch its first plant-based ham product by mid-year in 2,000 REWE supermarkets. A oversubscribes Series A financing laid the basis for this success
Paris-based drug delivery specialist Ceres Brain Therapeutics SA has raised €6m led by ANJAC, a French family-owned industrial group and preferred partner of healthcare laboratories and beauty and well-being brands, to support the clinical development neurological treatments.
Iceland’s Arctic Therapeutics has secured €26.5m in a Series A financing aimed to push its oral drug candidates AT-O01 and AT-004 into clinical trails in patients with rare amyloid aggregation diseases including Alzheimer’s disease.
EuropaBio calls for an ambitious cross-sectoral EU Biotech Act, that strengthens Europe as a global biotechnology leader for competitiveness and strategic autonomy.
The Safety Committee PRAC of the European Medicines Agency EMA is investigating a new potential adverse reaction to the appetite suppressant semaglutide. Epidemiological studies indicate that the rare eye disease non-arteritic anterior ischaemic optic neuropathy (NAION), which leads to blindness, could occur more frequently after treatment with the GLP-1 receptor agonist.
Thank you for a successful 2024!